Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2261
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation ; volume:17 ; number:1 ; day:6 ; month:9 ; year:2017 ; pages:1-11 ; date:12.2017
BMC cardiovascular disorders ; 17, Heft 1 (6.9.2017), 1-11, 12.2017
- Keyword
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Creator
-
Norby, Faye L.
- Contributor
-
Bengtson, Lindsay G.S
Lutsey, Pamela L.
Chen, Lin Y.
MacLehose, Richard F.
Chamberlain, Alanna M.
Rapson, Ian
Alonso, Álvaro
SpringerLink (Online service)
- DOI
-
10.1186/s12872-017-0672-5
- URN
-
urn:nbn:de:1111-201711114442
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Norby, Faye L.
- Bengtson, Lindsay G.S
- Lutsey, Pamela L.
- Chen, Lin Y.
- MacLehose, Richard F.
- Chamberlain, Alanna M.
- Rapson, Ian
- Alonso, Álvaro
- SpringerLink (Online service)
Other Objects (12)
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil
Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil
Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil
Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation